Bristol-Myers Squibb Co.

Latest Bristol-Myers Squibb Co. News and Updates

  • uploads///BMY
    Company & Industry Overviews

    How Bristol-Myers Squibb’s Key Products Performed in 1Q18

    Total sales for Bristol-Myers Squibb’s Opdivo increased 34%, from $1.1 billion in 1Q17 to $1.5 billion in 1Q18.

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    Major Developments for Johnson & Johnson in 3Q16

    Major developments As discussed previously in this series, Johnson & Johnson’s (JNJ) 3Q16 performance was positive across all of its segments. However, the Consumer segment reported a decline in revenue, as the negative impact of foreign exchange more than offset operational growth. There were several major developments for JNJ during 3Q16. Pharmaceuticals segment In 3Q16, the […]

    By Mike Benson
  • uploads///Analysts Reco
    Company & Industry Overviews

    Analysts’ Recommendations for Bristol-Myers Squibb in August 2017

    Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Merck Expects Modest Revenue Growth in Fiscal 2016

    Merck provided revenue guidance of $39.7 billion–$40.2 billion in 2016. It expects negative foreign exchange fluctuations to reduce its fiscal 2016 revenue.

    By Margaret Patrick
  • uploads///ISM
    Macroeconomic Analysis

    Expanding Service Sector Gives Relief to Economy in September

    With manufacturing slowing, a reading of the Non-Manufacturing Index at an above-neutral level (56.9) may provide some relief to the US economy, which is highly dependent on the service sector for its economic growth.

    By Lara Sheldon
  • uploads///Chart
    Company & Industry Overviews

    A Look at Johnson & Johnson’s Post-2Q17 Valuation

    Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed since its 2Q17 earnings announcement.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Are Analysts’ Recommendations for Merck in 2017?

    For 2016, Merck & Co. (MRK) reported revenue close to $39.8 billion, a year-over-year (or YoY) rise of ~1%. New product launches have played major roles in boosting Merck’s 2016 revenue.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Think about Bristol-Myers Squibb

    Of 28 analysts covering BMY’s stock, 42.3% gave it a “buy” recommendation, while 50.0% gave it a “hold” recommendation. Only 7.7% rated it as a “sell.”

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Celgene’s Revlimid Expected to Post Strong Revenue in 2017

    According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    What Analysts Project for Eli Lilly in 3Q17

    For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Did AGN’s US Medical Aesthetics Segment Contribute in 1Q16?

    Allergan’s US medical aesthetics segment includes facial aesthetics, medical dermatology products, and a wide range of silicone and saline breast implants.

    By Mike Benson
  • uploads///ccdafbcfbddefdffcb
    Company & Industry Overviews

    Market Response to EMA Validation of Opdivo Application

    BMY has four key oncology products, including Erbitux, Opdivo, Sprycel, and Yervoy. Two of these contributed more than $1 billion in 2014.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Label Expansion Expected to Boost Keytruda’s 2017 Revenue

    On October 24, 2016, the FDA approved Merck & Co’s (MRK) Keytruda as a second-line therapy for patients suffering from non-small cell lung cancer (or NSCLC).

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    Understanding the Revenue Fall in AstraZeneca’s Largest Segment in 3Q16

    AstraZeneca’s (AZN) CVMD (Cardiovascular and Metabolic Disease) segment contributed nearly 32.4% of total company revenues in 3Q16.

    By Mike Benson
  • uploads///Graph
    Miscellaneous

    Bristol-Myer Squibb’s Opdivo Is Keytruda’s Strong Competitor

    the U.S. Food and Drug Administration accepted the filing of a supplemental Biologics License Application for Bristol-Myers Squibb’s Opdivo.

    By Margaret Patrick
  • uploads///Costs
    Earnings Report

    Bristol-Myers Squibb’s Profitability and Financial Guidance

    Bristol-Myers Squibb estimates that its revenues will be between $15.5 billion and $15.9 billion, which is nearly flat as compared to 2014 revenues of $15.9 billion.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Could Expand Keytruda’s Revenues?

    In addition to the US market, Merck’s (MRK) Keytruda has been approved in more than 50 international markets for metastatic melanoma.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Inside Celgene’s Revlimid: Strong Patient Demand in 4Q16

    After the approval of the drug as a therapy for newly diagnosed multiple myeloma, Celgene’s Revlimid has witnessed rapid growth in market share worldwide.

    By Margaret Patrick
  • uploads///Analysts ratings
    Company & Industry Overviews

    Novartis on the Street: Analysts’ Recommendations in November

    Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold.”

    By Daniel Collins
  • uploads///xtandi market share
    Company & Industry Overviews

    How Xtandi Fueled Big Pharmaceutical Interest in Medivation

    Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.

    By Jillian Dabney
  • uploads///Graph
    Earnings Report

    AbbVie’s Viekira Pak Saw Weaker-than-Expected Performance

    Viekira Pak managed to earn revenues worth about $414 million in 1Q16. The drug’s sales in the US market, however, fell YoY (year-over-year) by about 9.3% and reached $125 million in 1Q16.

    By Margaret Patrick
  • uploads///molecule _
    Company & Industry Overviews

    Wall Street Analysts: Mostly Positive on Opko Health in July

    On July 11, Opko Health (OPK) stock closed at $6.01, which represents 126% growth from its 52-week low of $2.66 in March.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    Biogen Pursuing Investigational Candidates in Alzheimer’s Disease

    Biogen (BIIB) has entered into a licensing agreement with Bristol-Myers Squibb (BMY) for exclusive global rights for the development and commercialization of BMS-986168.

    By Margaret Patrick
  • uploads///Neuroscience
    Earnings Report

    Bristol-Myers Squibb’s Neuroscience and Immunoscience Segments

    Sales for Bristol-Myers Squibb’s (BMY) neuroscience segment declined over 80% in 2Q15, while the immunoscience segment’s sales improved ~15% in 2Q15 as compared to 2Q14.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Bristol-Myers Squibb’s Other Segments

    Sales from Bristol-Myers Squibb’s Neuroscience segment declined by 94% in 1Q16. Sales from the Immunoscience segment improved by ~18.7% in 1Q16 over 1Q15.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Hopes to Commercialize Next-Generation HCV Regimen by 2017

    AbbVie (ABBV) plans to complete its Phase 3 registrational program for investigational next-generation Hepatitis C virus (or HCV) therapy by 2016.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    How Analysts Rate Bristol-Myers Squibb in 1Q18

    Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analyzing Johnson & Johnson’s 1Q18 Profitability

    Johnson & Johnson (JNJ) reported revenues of $20.0 billion during 1Q18, 12.6% growth as compared to revenues of $17.8 billion during 1Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca Is Taking Steps to Improve Its Position in Oncology

    During the last quarter, the oncology segment’s contribution to AstraZeneca (AZN) increased to over 15%. AZN’s key products for oncology are Zoladex, Faslodex, Iressa, and the new drug Tagrisso.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    European Medicines Agency Validates Merck’s Keytruda Combo

    Merck’s (MRK) Keytruda (pembrolizumab) is approved to treat various forms of cancer.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Did Bristol-Myers Squibb’s Other Segments Perform in 3Q16?

    Bristol-Myers Squibb’s (BMY) neuroscience segment sales fell over 37% in 3Q16, while the immunoscience segment sales rose ~18% in 3Q16 as compared to 3Q15.

    By Mike Benson
  • uploads///RD
    Company & Industry Overviews

    What Were Pfizer’s Major Achievements in 2016?

    During 2016, Pfizer (PFE) succeeded in expanding its label for Ibrance, its breast cancer treatment.

    By Jillian Dabney
  • uploads///becdaabdacaceddd
    Earnings Report

    Johnson & Johnson Stock Remained Neutral to 2Q15 Earnings

    Due to the decelerating revenue growth over all segments, Johnson & Johnson (JNJ) reported a decrease in its top line by ~8.8% in its 2Q15 earnings release on July 14, 2015.

    By Mike Benson
  • uploads///Chart  Other
    Earnings Report

    A Look at Bristol-Myers Squibb’s Other Segments in 1Q17

    Bristol-Myers Squibb’s (BMY) other segments include the Neuroscience segment, the Cardiovascular segment, and the Immuno-Science segment.

    By Mike Benson
  • uploads///pharma division performance
    Earnings Report

    Sales Performance Analysis of Roche’s Pharmaceuticals Division

    Roche Holding (RHHBY) generated ~78% of its group sales from the pharmaceuticals division.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017

    On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novartis Focuses on Portfolio Prioritization to Boost Profitability

    To ensure long-term relevance as well as quick adaptability to changing market needs, Novartis (NVS) is focusing on five major initiatives in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Opdivo Is a Key Growth Driver for Bristol-Myers Squibb in 2016

    On November 10, 2016, the FDA approved Opdivo as a treatment option for patients suffering with recurring or metastatic squamous cell carcinoma of the head and neck (or SCCHN).

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    The High Hope of Exelixis’s Cabometyx Label Expansion

    Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.

    By Margaret Patrick
  • uploads///revue ee
    Earnings Report

    BioMarin’s Disappointing 3Q16 Earnings

    BioMarin Pharmaceutical (BMRN) reported its 3Q16 earnings on October 27, 2016. Revenues were $279.9 million, which was lower than Wall Street analysts’ projections.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Strengthens Its Position in the Virology Segment

    In addition to Humira, AbbVie also offers several virology drugs targeting diseases such as hepatitis C, HIV, and respiratory syncytial virus.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18

    Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

    By Mike Benson
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Seattle Genetics and Bristol-Myers Initiate ADCETRIS Trial

    On December 23, 2015, Seattle Genetics and Bristol-Myers Squibb announced the initiation of Phase 1 and 2 clinical trials of ADCETRIS.

    By Peter Neil
  • uploads///Graph
    Earnings Report

    Medicaid Restrictions Are Affecting Gilead’s Hepatitis C Drug Sales

    Since the launch of Sovaldi in late 2013, Gilead Sciences has managed to treat about 1,000,000 hepatitis C (or HCV) patients globally.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca May Witness a Fall in 2017 Net Profit Margin

    Wall Street analysts have projected AstraZeneca’s (AZN) 2017 net profit margins at about 12.2%, which is lower by 300 basis points on a YoY basis.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Other Drugs for Non-small Cell Lung Cancer

    Approximately 85% of all lung cancers in the United States are non-small cell lung cancers, and 10% to 15% of these are EGFR mutation-positive.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis’s 3Q16 Estimates: Innovative Medicines Segment

    Novartis’s Innovative Medicines segment, formerly referred to as the Pharmaceutical segment, consists of products for a variety of therapeutic areas.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Tagrisso Expected to Be a Key Growth Driver for AstraZeneca in 2017

    Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.

    By Margaret Patrick
  • uploads///Eliquis and Sprycel
    Company & Industry Overviews

    Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17

    In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Novartis’s 4Q16 Estimates: Innovative Medicines Segment

    The overall contribution of the Innovative Medicines segment is ~67% of Novartis’s total revenues.

    By Mike Benson
  • uploads///Graph
    Miscellaneous

    FDA Granted Breakthrough Therapy Status to Merck’s HCV Therapy

    The U.S. Food and Drug Administration (or FDA) granted breakthrough therapy designation to Merck’s (MRK) grazoprevir/elbasvir (100mg/50mg) combination therapy.

    By Margaret Patrick
  • uploads///Nephrology
    Company & Industry Overviews

    How Amgen’s Nephrology Drugs Are Positioned after 2Q17?

    In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.

    By Daniel Collins
  • uploads///virus _
    Earnings Report

    Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates

    Bristol-Myers Squibb beat Wall Street analysts’ estimates for earnings per share and revenues in 1Q18.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Xtandi’s Prescription Volumes Continue to Rise in 2017

    In this series, we’ll look at Pfizer’s main revenue drivers in 2017, and what could steer its performance in 2018.

    By Margaret Patrick
  • uploads///projections
    Earnings Report

    Johnson & Johnson’s Q2 2018 Earnings Estimates

    As per Wall Street analysts estimates, Johnson & Johnson (JNJ) is expected to report adjusted EPS (earnings per share) of $2.07 in the second quarter of fiscal 2018.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Bristol-Myers Squibb: What Do Its Other Segments Offer?

    Bristol-Myers Squibb’s (BMY) neuroscience segment’s sales declined by 63.0% in 2015 from 2014, while its immunoscience segment’s sales improved ~14.1%.

    By Mike Benson
  • uploads///long term strtegy
    Earnings Report

    Inside Roche’s Strategy to Offset Revenue Declines

    Roche’s big three contributors include MabThera/Rituxan, Herceptin, and Avastin, which accounted for 14.7%, 13.9% and 13.7% of revenues in fiscal 1Q16.

    By Jillian Dabney
  • bristol myers squibb good stock to buy
    Financials

    Is Bristol-Myers Squibb a Good Investment?

    Is Bristol-Myers Squibb a Good Stock to Buy?
    By Ruchi Gupta
  • uploads///Graph
    Company & Industry Overviews

    AbbVie’s Rova-T and the Treatment of Small Cell Lung Cancer

    AbbVie (ABBV) expects to secure FDA (U.S. Food & Drug Administration) approval in the third-line plus small cell lung cancer (or SCLC) indication in 2018.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Inside Novartis’s Eye Care Performance in 4Q16

    Alcon, NVS’s eye care segment, saw its 4Q16 revenues fall ~2% to ~$1.4 billion, including no change in sales but a -2% impact from foreign exchange.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Eli Lilly’s Cardiovascular Products Have Been Faring

    Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes cardiovascular products such as Cialis, Effient, and other products.

    By Mike Benson
  • uploads///pill _
    Healthcare

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

    By Kenneth Smith
  • uploads///PD  class action
    Company & Industry Overviews

    Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class

    The PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) class consists of Bristol-Myers Squibb’s Opdivo, Merck’s Keytruda, and Roche’s Tecentriq.

    By Jillian Dabney
  • uploads///microbiology Picture
    Company & Industry Overviews

    Wall Street Analysts Are Mostly Positive about Johnson & Johnson

    In June, Johnson & Johnson (JNJ) accepted a binding offer from Platinum Equity to acquire its LifeScan business for ~$2.1 billion.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    How AstraZeneca’s Oncology Products Performed in 4Q17

    AstraZeneca’s (AZN) oncology products include legacy oncology products as well as new oncology products.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Are Analysts Estimating for Allergan Today?

    AGN’s analysts estimate EPS of $4.72 on revenues of $4.27 billion for 4Q17, which would be 10.5% higher YoY (year-over-year).

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Behind Bristol-Myers Squibb’s Continued Growth in 1Q16

    Bristol-Myers Squibb (BMY) reported a growth of 9% in 1Q16. Analyst estimates forecast a high-single-digit growth to low-double-digit in revenues in 2016.

    By Mike Benson
  • uploads///tesla renaissance technologies
    Consumer

    How Did Tesla Become Renaissance Technologies’ Gem?

    In the fourth quarter of 2019, Tesla was Renaissance Technologies’ second-largest holding. Renaissance is one of the largest hedge funds in the US.

    By Rabindra Samanta
  • uploads///stock trading monitor desk
    Consumer

    Renaissance Technologies: Analyzing Its Q3 13F

    At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.

    By Rabindra Samanta
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Rapidly Advancing Its 2018 Solid Tumor Portfolio

    AbbVie (ABBV) is currently evaluating more than 20 investigational therapies targeting solid tumors. Seventeen of them are in Phase 1 trials.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AbbVie’s Rova-T: Solid Growth Driver for the Future?

    AbbVie (ABBV) aims to position its investigational therapy Rova-T (rovalpituzumab tesirine) as a standard of care treatment for patients with SCLC (small cell lung cancer).

    By Margaret Patrick
  • uploads///Fed meeting
    Company & Industry Overviews

    Could the Fed Trigger an S&P 500 Crash This Week?

    The S&P 500 Index, which is trading close to an all-time high, could be affected by the Fed’s tone in its upcoming meeting.

    By Maitali Ramkumar
  • uploads///brett jordan pDFJpuprE unsplash
    Healthcare

    Bristol-Myers Squibb: Could BMY Stock Surge Higher?

    Is Bristol-Myers Squibb stock undervalued, and could it surge higher anytime soon? Find out why further upside is possible for BMY.

    By Oleksandr Pylypenko
  • uploads///SGEN
    Company & Industry Overviews

    Analyzing Seattle Genetics’ Key Collaborations

    Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries.

    By Kenneth Smith
  • uploads///AdobeStock_
    Company & Industry Overviews

    Amgen and Celgene’s Otezla Deal: Key Highlights

    On August 26, Amgen (AMGN) announced the purchase of leading immunology drug Otezla from Celgene (CELG) for a cash consideration of $13.4 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    NVS or BMY: Who’s Expected to Post Faster Revenue Growth in 2019?

    According to the company’s fourth-quarter earnings conference call, Novartis expects to complete the spin-off of its Alcon business in the second quarter of 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Novartis Is Transforming Its Structure in 2019

    Since fiscal 2018, Novartis (NVS) has been focused on transforming itself into a new focused medicines company.

    By Margaret Patrick
  • uploads///AdobeStock_
    Earnings Report

    What to Expect From Bristol-Myers Squibb in Q2

    Bristol-Myers Squibb will release its second-quarter earnings on Thursday. The revenues will likely rise 7.16% YoY to $6.11 billion in the second quarter.

    By Margaret Patrick
  • uploads///people _
    Company & Industry Overviews

    Bristol-Myers Squibb: Losing Otezla Might Be Challenging

    In the latest update on the pending merger with Celgene (CELG), Bristol-Myers Squibb (BMY) proposed plans to divest Otezla—Celgene’s top-selling non-biologic psoriasis drug.

    By Margaret Patrick
  • uploads///icon _
    Company & Industry Overviews

    What Analysts Recommend for Pfizer and Bristol-Myers Squibb

    This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let’s take a closer look at each.

    By Margaret Patrick
  • uploads///business _
    Company & Industry Overviews

    Comparing PFE’s and BMY’s Immunology Drugs

    Pfizer’s (PFE) commercialized JAK (Janus kinase) inhibitor, Xeljanz, is approved for treating rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

    By Margaret Patrick
  • uploads///dollar _
    Company & Industry Overviews

    Comparing PFE’s and BMY’s Expense Trends

    Pfizer (PFE) has guided for fiscal 2019 adjusted costs of sales as a percentage of revenue of 20.8%–21.8%, and adjusted selling, informational, and administrative expenses of $13.5 billion–$14.5 billion.

    By Margaret Patrick
  • uploads///pills _
    Company & Industry Overviews

    What Investors Should Know about BMY-CELG Deal

    Bristol-Myers Squibb (BMY) issued a press release announcing shareholder approval of its proposed acquisition of Celgene in April.

    By Margaret Patrick
  • uploads///immunology _
    Company & Industry Overviews

    How Will Bristol-Myers Squibb’s Immunology Portfolio Evolve?

    Bristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) is expected to make the combined company a top-five player in the I&I (immunology and inflammation) space.

    By Margaret Patrick
  • uploads///cancer _
    Company & Industry Overviews

    What to Expect from Bristol-Myers Squibb’s Oncology Portfolio

    Bristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) is expected to result in a dominant player in IO (immuno-oncology), solid tumors, and hematology segments.

    By Margaret Patrick
  • uploads///technology _
    Company & Industry Overviews

    A Look at Bristol-Myers Squibb’s Near-Term Product Launches

    Bristol-Myers Squibb (BMY) highlighted the possibility of six new-term product launches after the completion of the acquisition of Celgene (CELG).

    By Margaret Patrick
  • uploads///personal _
    Company & Industry Overviews

    What to Expect from BMY’s Portfolio after Celgene Acquisition

    Bristol-Myers Squibb (BMY) estimated the value of currently marketed products of the combined company after completion of the acquisition of Celgene (CELG) to be $55 billion.

    By Margaret Patrick
  • uploads///money _
    Company & Industry Overviews

    Bristol-Myers Squibb Guides for Robust Rise in Revenues and EPS

    Bristol-Myers Squibb has guided for more than $45 billion of free cash flow in the first three years after completion of the deal.

    By Margaret Patrick
  • uploads///achievement _
    Company & Industry Overviews

    What’s the Latest on the BMY-Celgene Deal?

    Starboard Value has decided to give up the proxy war to stop Bristol-Myers Squibb’s deal with Celgene.

    By Margaret Patrick
  • uploads///merger _
    Healthcare

    Roche Holdings to Acquire Spark Therapeutics

    On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).

    By Margaret Patrick
  • uploads///cells _
    Earnings Report

    What Are Analysts Recommending for Merck after Q4 2018 Results?

    Of the 15 analysts covering Merck, six recommend a “strong buy,” seven recommend a “buy,” and two recommend a “hold.”

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bristol-Myers Squibb’s Revenue Forecast for Fiscal 2019

    In fiscal 2018, Bristol-Myers Squibb (BMY) reported revenues of $22.56 billion—a rise of 8.59% YoY (year-over-year).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Celgene and Bristol-Myers Squibb’s Deal: What Are the Benefits?

    Bristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) will add the latter’s blockbuster multiple myeloma (or MM) drugs, Revlimid and Pomalyst, to the company’s portfolio.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    BMY and Celgene to Form a Leading Global BioPharma Company

    According to Bristol-Myers Squibb’s (BMY) investor presentation, the company expects to create a leading oncology franchise across both solid tumor and hematologic malignancy segments.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bristol-Myers Squibbs and Celgene: Cost Synergies for Future Years

    According to Bristol-Myers Squibb’s (BMY) press release, the company expects the acquisition of Celgene (CELG) to result in annual cost synergies close to $2.5 billion.

    By Margaret Patrick
  • uploads///BMYcelgene
    Company & Industry Overviews

    What to Expect from BMY’s Celgene Acquisition

    The acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) brings together both the company’s leading franchises.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Bristol-Myers Squibb to Acquire Celgene

    Bristol-Myers Squibb has agreed to acquire Celgene in a cash and stock transaction valued at around $74.0 billion.

    By Daniel Collins
  • uploads///Xtandi
    Company & Industry Overviews

    Xtandi and Bosulif Are Expected to Boost Pfizer’s Revenue Growth

    In the first nine months of this year, Pfizer’s (PFE) Xtandi alliance revenue grew ~21% YoY (year-over-year) to $510.0 million.

    By Daniel Collins
  • uploads///PFE
    Company & Industry Overviews

    Analyzing Pfizer’s Revenues in December

    Pfizer’s net revenues were $39.7 billion in the first nine months of 2018—compared to $38.8 billion during the same period in 2017.

    By Daniel Collins
  • uploads///thermometer _
    Company & Industry Overviews

    Pfizer Stock Has Risen ~20% in 2018

    Pfizer’s (PFE) stock price opened at $36.23 on January 2 and reached $43.51 on November 16, which represents ~20.0% growth YTD.

    By Daniel Collins
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.